Morgan Stanley Aprea Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 14, 2023	SELL	$0.32 - $15.2 $11,569 - $549,571	-36,156 Reduced 11.59%	275,860 $91,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $13.6 $28,272 - $541,552	-39,820 Reduced 11.32%	312,016 $202,000
Q2 2022 Oct 27, 2022	BUY	$0.62 - $1.94 $65,033 - $203,490	104,892 Added 42.48%	351,836 $264,000
Q2 2022 Aug 15, 2022	BUY	$0.62 - $1.94 $65,033 - $203,490	104,892 Added 42.48%	351,836 $264,000
Q1 2022 Oct 27, 2022	SELL	$1.59 - $3.16 $166,778 - $331,458	-104,892 Reduced 29.81%	246,944 $459,000
Q1 2022 May 13, 2022	SELL	$1.59 - $3.16 $126,032 - $250,480	-79,266 Reduced 24.3%	246,944 $459,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $5.58 $405,376 - $788,152	141,246 Added 76.36%	326,210 $936,000
Q3 2021 Nov 15, 2021	BUY	$3.43 - $5.63 $634,426 - $1.04 Million	184,964 New	184,964 $945,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,831
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.